triple agonist retatrutide Reta clinical trial data & dosing — a must read (Reta) isn't just another GLP-1. It's a triple-agonist peptide studied in Phase 3 trials for metabolic health — targeting GLP-1, GIP Media Centre | EASD

Statistics on effectiveness of these procedures include: Reduces the risk of premature death by up to 50% Patients may lose as much as 60% of excess weight six months after surgery and over 75% a year after surgery Many patients experience remission or resolution of obesity-related diseases The vast majority of patients maintain their weight loss 10+ years after surgery These metabolic procedures are also incredibly safe

E., Goossens, G

Niacin (also known as Nicotinic Acid): This is the original form of Vitamin B3

Next, its difficult not to know about semaglutide (branded Ozempic or Wegovy) and tirzepatide (branded Mounjaro)